AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for NYSE:ABBV*
59.06
-0.39 (-0.66%)
Sep 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 59.01 - 59.93
52 week 44.01 - 60.02
Open 59.84
Vol / Avg. 13.99M/9.78M
Mkt cap 94.08B
P/E 22.78
Div/yield 0.42/2.84
EPS 2.59
Shares 1.59B
Beta     -
Inst. own 81%
Oct 23, 2014
Q3 2014 AbbVie Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 10, 2014
AbbVie Inc at Morgan Stanley Healthcare Conference
Sep 3, 2014
Infinity Pharmaceuticals Inc and AbbVie to Discuss Strategic Collaboration In Oncology Conference Call - Webcast
Jul 25, 2014
Q2 2014 AbbVie Inc Earnings Release
Jul 25, 2014
Q2 2014 AbbVie Inc Earnings Call - Webcast
Jul 18, 2014
AbbVie Inc To Discuss The Recommended Combination With Shire Plc - Webcast
Jun 25, 2014
AbbVie Conference Call to Discuss Possible Combination with Shire plc
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 22.29% 21.97%
Operating margin 30.76% 30.14%
EBITD margin - 36.59%
Return on average assets 15.26% 14.69%
Return on average equity 88.84% 105.11%
Employees 25,000 -
CDP Score - -

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
William J. Chase Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President - Business Development, External Affairs, General Counsel
Age: 50
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Roxanne S. Austin Independent Director
Age: 53
Bio & Compensation  - Reuters